Everolimus May Be Safe, Effective for Neuroendocrine Tumors

Share this content:
Treatment with everolimus was linked with improvement in progression-free survival in patients with progressive gastrointestinal or lung neuroendocrine tumors.
Treatment with everolimus was linked with improvement in progression-free survival in patients with progressive gastrointestinal or lung neuroendocrine tumors.

Treatment with everolimus was associated with significant improvement in progression-free survival in patients with progressive gastrointestinal or lung neuroendocrine tumors, a study published in the The Lancet has shown.1

Because there are limited effective systemic therapies for patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal tract, researchers sought to evaluate the safety and efficacy of everolimus compared with placebo as a potential treatment strategy in this patient population.

For the international, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, researchers enrolled 302 patients with advanced, progressive, well-differentiated, non-functional neuroendocrine tumors of the lung or gastrointestinal tract. Participants were randomly assigned 2:1 to receive everolimus 10 mg orally daily or placebo, in addition to supportive care.

Results showed that median progression-free survival was 11.0 months (95% CI, 9.2 - 13.3) in the everolimus arm and 3.9 months (95% CI, 3.6 - 7.4) in the placebo arm, corresponding to a 52% reduction in the estimated risk of progression or death with everolimus (HR, 0.48; 95% CI, 0.35 - 0.67; P < .00001).

Researchers also found that everolimus may be associated with an overall survival benefit as well (HR, 0.64; 95% CI, 0.40 - 1.05; P = .037), but the results of that interim analysis are not statistically significant.

In regard to safety, grade 3 or 4 everolimus-related adverse events were uncommon. Grade 3 or 4 stomatitis occurred in 9% of patients who received everolimus, diarrhea and infections each in 7%, anemia in 4%, and fatigue and hyperglycemia each in 3% of everolimus-treated patients.

“Everolimus is the first targeted agent to show robust anti-tumor activity with acceptable tolerability across a broad range of neuroendocrine tumors, including those arising from the pancreas, lung, and gastrointestinal tract,” the investigators concluded.

Reference

  1. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study [published online ahead of print December 15, 2015]. Lancet. doi: 10.1016/S014906736(15)00817-X.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs